Jake Van Naarden, Loxo@Lilly CEO

Lil­ly en­ters ripe BTK field with quick FDA nod in man­tle cell lym­phoma

Eli Lil­ly has suc­ceed­ed in its at­tempt to get the first non-co­va­lent ver­sion of Bru­ton’s ty­ro­sine ki­nase, or BTK, in­hibitors to mar­ket, push­ing it past ri­val Mer­ck.

The FDA gave an ac­cel­er­at­ed nod to Lil­ly’s dai­ly oral med, to be sold as Jaypir­ca, for pa­tients with re­lapsed or re­frac­to­ry man­tle cell lym­phoma.

The agency’s green light, dis­closed by the In­di­anapo­lis Big Phar­ma on Fri­day af­ter­noon, cat­a­pults Lil­ly in­to a field dom­i­nat­ed by co­va­lent BTK in­hibitors, which in­cludes Ab­b­Vie and John­son & John­son’s Im­bru­vi­ca, As­traZeneca’s Calquence and BeiGene’s Brukin­sa.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.